Motley Fool: Glaxo "above the fray"

The investment mavens at Motley Fool have good things to say about Glaxo, in part because of the relative lack of litigation against them.

Glaxo has certainly suffered from generic competition but has weathered the storm better than most. Trading at less than 17 times trailing earnings, the stock is cheaper than the average pharmaceutical company, yet still boasts high operating margins and one of the highest dividend yields in the industry.